Novo Nordisk Launches Wegovy in China at Lower Price Point

The weight-loss drug, approved in June, is now available as China faces rising obesity rates.

Wegovy is priced at 1,400 yuan ($193) in China, significantly lower than the US price of $1,349.
Novo Nordisk's drug targets adults with obesity or overweight individuals with weight-related health issues.
China's obesity rates have increased, with over half of the adult population being overweight or obese.
The drug is not covered by China's national health insurance, making it a self-funded option for patients.
Local companies are developing generic versions of Ozempic, another Novo Nordisk drug, to meet demand.